A

Adocia SA
PAR:ADOC

Watchlist Manager
Adocia SA
PAR:ADOC
Watchlist
Price: 7 EUR -1.13%
Market Cap: 128.1m EUR

Operating Margin
Adocia SA

-77.9%
Current
-577%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-77.9%
=
Operating Profit
-8.1m
/
Revenue
10.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Adocia SA
PAR:ADOC
126m EUR
-78%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
394.7B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.6B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD
28%
AU
CSL Ltd
ASX:CSL
86.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
8%
NL
argenx SE
XBRU:ARGX
43B EUR
22%
No Stocks Found

Adocia SA
Glance View

Market Cap
126m EUR
Industry
Biotechnology

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

ADOC Intrinsic Value
5.74 EUR
Overvaluation 18%
Intrinsic Value
Price
A
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-77.9%
=
Operating Profit
-8.1m
/
Revenue
10.4m
What is the Operating Margin of Adocia SA?

Based on Adocia SA's most recent financial statements, the company has Operating Margin of -77.9%.

Back to Top